Idiopathic Short Stature – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Idiopathic Short Stature – Drugs In Development, 2024 report and make more profitable business decisions.
Idiopathic short stature is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex, and population, in whom no identifiable disorder is present. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay.
The Idiopathic Short Stature drugs in development market research report provide comprehensive information on the therapeutics under development for Idiopathic Short Stature, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Short Stature and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Idiopathic Short Stature | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Idiopathic Short Stature therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Idiopathic Short Stature pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Idiopathic Short Stature treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Bolder Biotechnology IncBraasch Biotech LLC
Changchun GeneScience Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Lumos Pharma Inc
Novo Nordisk AS
Xiamen Amoytop Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Idiopathic Short Stature reports